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ABSTRACT
In continuation of studies in these laboratories aiming at the bioevaluation of macromolecular anticancer drug models, in vitro
cytotoxicity screens are performed on several series of water-soluble polymer-methotrexate conjugates. The methotrexate drug
in these conjugates is bound through amide or ester linkages to water-soluble polyamide- or polyamidoamine-type carriers by
previously developed anchoring techniques. Tests were conducted against the HeLa human cervical carcinoma cell line generally
considered to be drug-sensitive, and against two variants of the rather refractory Colo 320 DM, a human colon adenocarcinoma
line.
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1. Introduction
The concept of binding (conjugating) a medicinal agent to a
macromolecular carrier for the purpose of enhancing the drug’s
overall clinical effectiveness dates back to the mid-seventies,
and Helmut Ringsdorf must be credited with having laid the
groundwork for this highly successful technology2. It was in
Ringsdorf ’s laboratory where the prototype carrier-drug conju-
gate originated and the venerable anticancer agent, metho-
trexate, served in that work as the drug constituent.3 Subse-
quently, Ringsdorf ’s strategy was creatively utilized in other
laboratories, notably those of Ghose4 Chu and Howell5, Shen
and Ryser6, Garnett and Baldwin7, Kanellos8 and Deguchi9, with
co-workers, who pioneered the development of methotrexate
conjugates with antibodies and other natural, proteinaceous
polymers. Successful activities in this field have later been
reported also by Pouton and Marriott10, Stehle et al.11, Boratynski
et al.12, Ghosh et al.13, and most notably, by the prolific group of
Umemoto, Kato and Hara14. The subject has more recently been
reviewed by the last-named authors15. In our laboratory, man-
made, i.e. fully synthetic, macromolecules as drug carriers have
been given preference over proteinaceous and other natural
polymers for a number of incisive reasons elaborated previ-
ously1. Most importantly, such macromolecules can be con-
structed precisely by design in terms of structural types,
biodegradability, and frequency in the chain of the various sub-
units with solubilizing, drug-binding, and other facilitating
functions. Polyaspartamides lend themselves particularly well
to this application. Accordingly, as part of our ongoing
programme in carrier-bound drug development we recently
synthesized MTX conjugates in which the drug is anchored to
polyaspartamide carriers through short connecting segments
containing ester or carboxamide groups as the biofission-
able links. A preliminary in vitro evaluation of selected
polyaspartamide-MTX conjugates in screens against CEM
human leukemic lymphoblasts showed outstanding cytotoxic
behaviour1, prompting further exploratory work with this
conjugate system in tests against other cancer cell lines. In the
present communication we present the results of in vitro tests
performed against the Colo 320 DM human colon adeno-
carcinoma cell line. Colorectal malignancies are notoriously
unresponsive to chemotherapy, and the Colo line may therefore
serve as a useful tool to assess an anticancer agent’s ability to
circumvent drug resistance. The conjugates tested were pre-
dominantly of the polyaspartamide-MTX type, but several
conjugates with the drug bound to poly(amidoamine) carriers
were included in this project.
2. Experimental
2.1. General Procedures
1H NMR spectra (400 MHz; integration error limits, ±12%)
were taken on D2O solutions. Chemical shifts, , are given in
ppm relative to sodium 3-(trimethylsilyl)-2,2,3,3-d4-propionate;
unless stated otherwise, D2O solutions of polymeric materials
were routinely adjusted to pD 10 just prior to scanning to elimi-
nate spurious protonation. Inherent viscosities, inh, were deter-
mined with the aid of Cannon-Fenske viscometers in H2O at
30.0 ± 0.5°C; the concentration was c = 0.2 g 100 mL–1. Data are
reported in units of dL g–1. A VIRTIS Bench Top 3 freeze-drier
operating at –30°C, 0.1 torr, was used for the lyophilization of
aqueous polymer solutions. Dialysis was performed in Spectra/
Por 4 membrane tubing (12 000–14 000 molecular mass cut-off)
and in Spectra/Por 6 wet tubing (25 000 molecular mass cut-off),
for separation of second polymer fractions also in Spectra/Por 3
(6000 molecular mass cut-off). The operations were conducted
against frequently changed batches of magnetically stirred
H2O at specified pH. Size exclusion chromatography was per-
formed on Sephadex G-25. Polymer samples were dried in a
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SARTORIUS Thermo Control Infrared Drying System (heating
programme: 2 × 5 min at 65°C) or in an Abderhalden tube (2 d at
50°C) under reduced pressure.
Conjugates were tested in vitro against the HeLa human cervi-
cal epitheloid carcinoma and against two variants of the Colo
DM 320 human colon adenocarcinoma cell line. Tests were per-
formed over a 72 h period; the protocol has previously been
described16.
2.2. Solvents, Reagents, Reactants
Deionized water was used for preparative, chromatographic,
and dialysis operations. N,N-Dimethylformamide (DMF) and
N-methylpyrrolidone (NMP), both predried over Molecular
Sieves 4A, were redistilled under reduced pressure in a gentle
stream of N2; the first 5% of distillate was discarded. All other
solvents, laboratory grade, were used as received, and so were
the coupling agents, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophos-phate (HBTU) and 1-ethoxy-
carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), as well as
monomeric amines and other reactants (Fluka Chemie AG).
Methotrexate (+amethopterin, MTX) was a gift from Dr A.
Bogdanov; additional quantities were purchased from Fluka
Chemie. The compound was dried for 2 d at 40°C in an
Abderhalden tube under reduced pressure to remove water of
hydration.
Poly-DL-succinimide, the educt polymer for the poly-
aspartamide carriers, was prepared as a master batch by the
procedure of Neri and Antoni17; the mass-average molecular
mass derived from viscosity data18 was 31 600. The polymer,
finely pulverized, was dried in an Abderhalden tube (1 d,
70–75°C) under reduced pressure.
2.3. N-Protection of Diamines
The diamine monomers required for the synthesis of conju-
gates 19–24, 1,3-diaminopropane, diethylenetriamine, and
1,2-bis(2-aminoethoxy)ethane, were mono-N-protected with
the BOC (tert-butoxycarbonyl) group. The procedure described
below for the preparation of N-(tert-butoxycarbonyl)-1,3-
diaminoethane, is representative.
The solution of the BOC protection agent, di-tert-butyl
dicarbonate, 21.8 g (0.1 mol) in 140 mL of dry dioxan, was added
dropwise to a solution of 1,3-diaminopropane, 59.3 g (0.8 mol) in
60 mL of dioxan. After a stirring period of 1 d at ambient temper-
ature, the solvent, together with excess diamine, was removed
by rotatory evaporation at 50°C bath temperature. Water,
100 mL, was added to the residue, and a small portion of insolu-
ble N,N-bis-BOC-protected diamine was removed by filtration.
The filtrate was exhaustively extracted with several 50-mL
portions of methylene chloride; this left any residual unreacted
diamine as the most hydrophilic constituent in the aqueous
phase. From the combined extracts, dried over anhydrous
MgSO4, the solvent was removed on a rotavapor, leaving
N-BOC-1,3-diaminopropane as an oily liquid in a yield of 12.5 g
(72%). The crude compound, giving a very clean 1H NMR spec-
trum, was used as collected.
1H NMR,/ppm: 3.1 (t), 2H (CONHCH2); 2.66 (t), 2H (CH2NH2);
1.6 (m), 2H (CH2CH2CH2); 1.46 (s), 9H (CH3).
For the preparation of N-(tert-butoxycarbonyl)-1,4,7-triaza-
heptane, diethylenetriamine, 31 g (300.7 mmol) dissolved in
50 mL of dioxan, was treated with the BOC reagent, 9.2 g
(42 mmol), predissolved in 60 mL of the same solvent. Work-up
as in the preceding experiment afforded 7.1 g (83%) of oily liquid.
1H NMR, /ppm: 3.2 (t), 2H (CONHCH2); 2.65 (m), 6H ( remain-
ing CH2); 1.46 (s), 9H (CH3).
The third N-protected diamine, N-(tert-butoxycabonyl)-4,7-
dioxa-1,10-diazadecane, was prepared in an analogous fashion
from 1,2-bis(2-aminoethoxy)ethane, 69.7 g (470 mmol), and
BOC-reagent, 14.8 g (68 mmol). The crude, oily product was
obtained in a yield of 14.3 g (85%).
1H NMR, /ppm: 3.7 (s), 4H (OCH2CH2O); 3.6 (m), 4H
(NHCH2CH2O); 3.2 (t), 2H (CONHCH2); 2.7 (t), 2H (CH2NH2);
1.45 (s), 9H (CH3).
2.4. MTX Conjugates
Amounts of conjugates and precursor polymers are given as
base moles and thus refer to the simplest recurring units defined
by structures 1 to 24 normalized to y = 1 (x = 1 in 25).
Conjugate 1. The carrier serving as the educt polymer for this
conjugate, poly-,-DL-[N-(3-(dimethylamino)propyl)aspar-
tamide(95)-co-N-(3-aminopropyl)aspartamide(5)], was pre-
pared from polysuccinimide by stepwise aminolytic ring open-
ing as previously described1. Briefly, 3-(dimethylamino)propyl-
amine, 971 mg (9.5 mmol), dissolved in 1 mL of DMF, was added
to the stirred solution of polysuccinimide, 970 mg (10 mmol)
in 6 mL of DMF. The N2-saturated solution was stirred for 8 h
at room temperature and subsequently added dropwise to
1,3-diaminopropane, 111 mg (1.5 mmol), predissolved in 8 mL of
DMF and stirred in an ice bath. Upon resaturation with N2,
stirring was continued for 20 h in the ice bath and for another 1 h
at ambient temperature. Moisture access was strictly precluded
up to this point to prevent hydrolytic imide ring opening in the
educt polymer. Partial solvent removal under reduced pressure
(bath temperature <50°C) and precipitation with excess
Et2O-hexane (2:1) afforded a resinous product, which was
washed thoroughly with hot toluene and Me2CO for removal of
monomeric amine. Redissolved in 10 mL of H2O, with pH
adjusted to 7–8, the product was dialysed for 2 d in Spectra/Por 4
and for another 2 d in Spectra/Por 6 tubing against frequently
changed, magnetically stirred batches of H2O. For the last 6 h of
the second dialysis step, the retentate pH was raised to 9 (aq.
ammonia) to eliminate N protonation. Freeze-drying and
post-drying in the SARTORIUS unit gave water-soluble carrier
polymer in a yield of 960 mg (48.5%).
1H NMR, /ppm (expected proton counts in parentheses): 3.2,
38H (40H; CONHCH2); 2.8–2.3, 83H (80H; NHCOCH2,
CH2N(CH3)2, CH2NH2); 2.2 112H (114H; CH3); 1.75, 40H (40H;
CH2CH2CH2).
A 0.1 mmol sample of the carrier, 396 mg, dissolved in 8 mL of
DMF, was treated with MTX, 56 mg (0.12 mmol), added in small
portions with stirring. EEDQ, 30 mg (0.12 mmol), dissolved in
2 mL of NMP, was added dropwise, and so was triethylamine,
24 mg (0.24 mmol). Upon saturation with N2, the resulting solu-
tion was stirred for 24 h at ambient temperature and for another
0.5 h at 50°C. Precipitation of the polymeric conjugate was
brought about by addition of excess Et2O-hexane (2:1) to the
precooled solution, and the resinous polymer was redissolved in
20 mL of H2O. For dissociation and removal of unreacted MTX
the pH was adjusted to 10 (Na2CO3), and the solution was passed
through a column (1.5 × 15 cm) charged with Sephadex G-25
and equilibrated with H2O at that pH. The eluate (exclusion
volume) containing the light-yellow product band was dialysed
for 2 d in Spectra/Por 6 tubing against H2O at pH 6.8. For the last
5 h of this treatment the retentate pH was lowered to 4 (0.1 M
HCl) and after several minutes raised again to 6 (aq. ammonia);
this served to liberate the pendent carboxyl group of MTX from
its Na salt. Freeze-drying of the retentate afforded conjugate 1 as
a yellow, water-soluble solid in a yield of 247 mg (56.3%).
1H NMR, /ppm: 8.6–6.6, with individual signals at 8.6, 7.7, and
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6.7, 4.8H (1H + 2H + 2H = 5H; aromatic and heteroaromatic CH
of MTX); 1.7, 40H (40H; CH2CH2CH2). The data indicate 96%
MTX incorporation of available NH2 sites, corresponding to 9.9%
by mass.
The combined outer phases collected in the dialysis operation
were redialysed for 2 d in Spectra/Por 3 tubing, and from the
retentate another portion, 105 mg (24%), of lower-molecular
conjugate was isolated as a yellowish, water-soluble solid with
an MTX content of 8.5% by mass (NMR).
Conjugate 2. The precursor polymer, poly-,-DL-[N-(3-
(dimethylamino)propyl)-aspartamide(90)-co-N-(3-aminopropy
l)aspartamide(10)], was synthesized from polysuccinimide
(10 mmol), 3-(dimethylamino)propylamine (9 mmol), and
1,3-diaminopropane (3 mmol) in a total of 15 mL of DMF by the
general procedure described for the carrier of 1. The wa-
ter-soluble carrier was isolated in 55% yield.
1H NMR, /ppm: 3.2, 20H (20H; CONHCH2); 2.8-–2.3, 37H
(40H; NHCOCH2, CH2N(CH3)2, CH2NH2); 2.2, 55H (54H; CH3);
1.7, 20H (20H; CH2CH2CH2).
A 0.1 mmol sample of the carrier, 196 mg, was dissolved in 4 mL
of DMF together with MTX, 56 mg (0.12 mmol). A solution of
HBTU, 42 mg (0.11 mmol), in 0.5 mL of DMF was added with stir-
ring, and so was triethylamine, 26 mg (0.26 mmol). N2 saturation
was followed by further stirring for 2 h at ambient temperature.
A slight turbidity appearing during the stirring period was elimi-
nated by the addition of 0.5 mL of NMP. Precipitation and
further work-up as described for 1 gave 125 mg (51%) of 2 as a
yellow, water-soluble solid.
1H NMR, /ppm: 8.6–6.5 combined, 4.7H (5H; aromatic and
heteroaromatic CH of MTX); 1.7, 20H (20H; CH2CH2CH2). The
data indicate 94% NH2 substitution by MTX, corresponding to
an MTX content of 16.5% by mass.
Conjugate 3. The carrier polymer, poly-,-DL-[N-(3-
(dimethylamino)propyl)aspartamide-(80)-co-N-(3-aminopropy
l)aspartamide(20)], was synthesized as described for the precur-
sor to 1, except with these reagent amounts: polysuccinimide,
10 mmol; 3-(dimethylamino)- propylamine, 8 mmol;
1,3-diaminopropane, 6 mmol; in a total of 16 mL of DMF. The
yield of water-soluble carrier was 54%.
1H NMR,/ppm: 3.3–3.2, 10.5H (10H; CONHCH2); 2.8–2.3, 17H
(20H; NHCOCH2, CH2N(CH3)2 CH2NH2); 2.2, 25H (24H; CH3);
1.7-1.6, 10H (10H; CH2CH2CH2).
MTX conjugation to this carrier was achieved by the procedure
used for the preparation of 2, the amounts of reactants and
reagents in the feed being: carrier, 0.2 mmol; MTX, 0.26 mmol;
HBTU, 0.22 mmol; NEt3, 0.52 mmol. Yield, 53%.
1H NMR, /ppm: 8.6–6.6 combined, 4.7H (5H; aromatic and
heteroaromatic CH of MTX); 1.7, 10H (10H; CH2CH2CH2). These
data indicate an MTX incorporation of 94%, corresponding to
30.9% by mass.
Conjugate 4. The carrier, poly-,-DL-[N-(3-(dimethy-
lamino)propyl)aspartamide(75)-co-N- (3-aminopropyl)asparta-
mide(25)], was prepared as previously described19 (there desig-
nated 11 (75)).
1H NMR, /ppm: 3.3–3.1, 8H (8H; CONHCH2); 1.8, 8H (8H;
CH2CH2CH2).
The drug was conjugated to the carrier as in the preceding
experiments. The yellow, water-soluble conjugate was collected
in 39% yield.
1H NMR, /ppm: 8.6–6.5 combined, 4.1H (5H; aromatic and
heteroaromatic CH of MTX); 1.8-1.7, 8H (8H; CH2CH2CH2). A
coupling extent of 82% was indicated by these data.
The conjugate was retreated with 0.4, 0.3, and 0.8 equivalents
of MTX, HBTU, and NEt3, respectively, for 3 h at room tempera-
ture and was conventionally worked up. Recovery yield, 59%.
1H NMR,/ppm: 8.6–6.5, 4.8H (5H), indicating 96% MTX incor-
poration (36.2% MTX by mass).
Conjugates 5-11 These were taken from the preceding investi-
gation1, there designated 5, 6, 7, 4, 8, 10 and 11, respectively.
Conjugate 12. The required carrier, poly-,-DL-[N-(2-
hydroxyethyl)aspartamide(90)-co-N-(3-amino-2-hydroxy-
propyl)aspartamide(10)], was synthesized in 57% yield by the
general procedure described for the carrier of 1, with these reac-
tants and amounts: polysuccinimide, 970 mg (10 mmol),
ethanolamine, 550 mg (9 mmol), and 1,3-diaminopropan-2-ol,
270 mg (3 mmol), in a total of 19 mL of DMF.
1H NMR, /ppm: 3.7, 19H (19H; CH2OH, CHOH); 3.3–3.2,
19.8H (20H; CONHCH2).
Drug coupling was achieved by treatment of the carrier,
400 mg (0.248 mmol), dissolved in 7 mL of DMF, with a solution
of MTX, 135 mg (0.298 mmol), in 2 mL of the same solvent, fol-
lowed by the dropwise addition of HBTU, 101 mg (0.273 mmol),
dissolved in 1 mL of DMF, and NEt3, 50 mg (0.5 mmol). The
N2-saturated solution was stirred for 2 h at room temperature,
and the product was worked up by the conventional procedure.
There was obtained 380 mg (74.2%) of yellow, water-soluble 12.
1H NMR, /ppm: 8.5–6.5 combined, 4.75H (5H; aromatic and
heteroaromatic CH of MTX); 3.7, 19H (19H; CH2OH, CHOH).
The data indicate 95% NH2 substitution by MTX, corresponding
to an MTX content of 21.2%.
Conjugates 13-15. These were taken from the previous study1,
there numbered 12, 13 and 14, respectively.
Conjugate 16. The carrier, poly-,-DL-[N-(3,6-dioxa-
hexyl)aspartamide(90)-co-N-(3-amino-2-hydroxypropyl)
aspartamide(10)], was synthesized as described for the carrier
in the foregoing experiment, except that ethanolamine was
replaced by an equal amount of 2-(2-amino-ethoxy)ethanol. The
water-soluble carrier was collected in 61% yield.
1H NMR, /ppm: 3.8–3.7, 55H (55H; O(CH2)2OCH2, CHOH);
3.4–3.2, 19H (20H; CONHCH2).
MTX conjugation as described for 12 afforded conjugate 16 as a
yellow, water-soluble solid in 69% yield.
1H NMR, /ppm: 8.6–6.5 combined, 5H (5H; aromatic and
heteroaromatic CH, MTX); 3.8–3.5, 55H (55H; O(CH2)2OCH2,
CHOH). The data indicate 100% NH2 substitution by MTX,
corresponding to an MTX content of 18.5%.
Conjugate 17, 18. These conjugates with ester-bound MTX
were taken from an earlier project20, there designated
1-MTX(10.8) and 2-MTX(8.9), with MTX contents of 19.8 and
18.7%, respectively.
Conjugate 19. For the preparation of the carrier polymer,
ethylenebisacrylamide, 2.48 g (16 mmol) was dissolved with
warming in 20 mL of H2O. After cooling to ambient tempera-
ture, N-(tert-butoxycarbonyl)-1,3-diaminopropane, 558 mg
(3.2 mmol), was added and dissolved. The resulting solution,
saturated with N2, was stirred for 1 d at room temperature and
for another 20 h at 50°C. Upon the addition of 3-(dimethylamino)
propylamine, 1.31 g (12.8 mmol), the solution was resaturated
with N2. Stirring was continued for 40 h at 55–60°C and, after the
addition of ethanolamine, 49 mg (0.8 mmol), for another 1 h at
that temperature. The last-named step served to eliminate any
terminal vinyl groups in the product as a potential cause of sub-
sequent crosslinking. Complete solvent removal under reduced
pressure (50°C bath temperature) was followed by stirring (1 h)
of the residue with 5 mL of trifluoroacetic acid for N-deprotec-
tion. Excess acid was removed by rotatory evaporation (30°C
bath temperature). The product polymer was precipitated with
excess Et2O-EtOH-hexane (2:1:2), thoroughly washed with hot
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toluene, and redissolved in 20 mL of H2O. The solution, with
pH adjusted to 7, was dialysed for 2 d in Spectra/Por 4 tubing and
for another 2 d in Spectra/Por 6 tubing. Freeze-drying and
post-drying on the SARTORIUS unit gave 559 mg (14%) of
carrier polymer as a water-soluble solid.
1H NMR, /ppm: 4.54, 10H (10H; NHCH2NH); 2.75, 20.5H
(20H; NHCOCH2); 2.7–2.25, 44H (40H; CH2N(CH2)(CH2),
CH2NH2, CH2N(CH3)2); 2.21, 24.5H (24H; CH3); 1.6, 10.2H (10H;
CH2CH2CH2).
The carrier so obtained was conjugated with MTX by a method
similar to that used for the preparation of conjugates 1–18. A
200-mg portion of the carrier (0.16 mmol) was dissolved in 5 mL
of DMF. MTX, 87 mg (0.192 mmol) was added and dissolved,
followed by the dropwise addition of HBTU 66 mg (0.178 mmol),
predissolved in 0.5 mL of DMF, and then, triethylamine, 32 mg
(0.319 mmol). After saturation with N2, the solution was stirred
for 2h at ambient temperature. From the cooled (~5°C) solution,
the conjugate was precipitated with excess Et2O-Me2CO (2:1),
redissolved in 5 mL of H2O, and further treated as described for
conjugate 1. This gave yellow, water-soluble conjugate 19 in a
yield of 136 mg (49.8%).
1H NMR, /ppm: 8.5–6.5 combined, 4.9H (5H; aromatic and
heteroaromatic CH of MTX); 4.55 10H (10H; NHCH2NH); 1.75,
9.5H (10H; CH2CH2CH2). The data indicate 98% substitution of
available NH2 groups by MTX, corresponding to an MTX con-
tent of 26.4% by mass.
Conjugate 20. The water-soluble carrier was synthesized in
17% yield as described in the foregoing, except that N-BOC-
1,3-diaminopropane was replaced by an equal amount of N(tert-
butoxycarbonyl)-1,4,7-triazaheptane.
1H NMR, /ppm: 4.55, 10H (10H; NHCH2NH); 2.8, 22H (20H;
NHCOCH 2 ) ; 2 .76–2.5, 48H (44H; CH 2 N(CH 2 )(CH 2 ) ,
CH2NHCH2CH2NH2, CH2N(CH3)2); 2.21, 22H (24H; CH3); 1.6, 7H
(8H; CH2CH2CH2).
Conventional conjugation with MTX as described for 19 gave
yellow, water-soluble conjugate 20 in 53% yield.
1H NMR, /ppm: 8.5–6.5 combined, 4.95H (5H; aromatic and
heteroaromatic CH of MTX); 1.6, 8H (8H; CH2CH2CH2). The
extent of MTX incorporation was thus 99%, corresponding to an
MTX content of 26.0% by mass.
Conjugate 21. The water-soluble carrier was prepared in 18.6%
yield by the general procedure used for the carrier of 19; how-
ever, N-BOC-1,3-diaminopropane was replaced by an equal
amount of N-(tert-butoxycarbonyl)-4,7-dioxa-1,10-diazadecane.
1H NMR, /ppm: 4.5, 10H (10H; NHCH2NH); 3.65–3.5, 9H (8H;
CH2OCH2); 2.8–2.23, 64H (60H; NHCOCH2, CH2N(CH2)(CH2),
CH2NH2, CH2N(CH3)2); 2.2, 23H (24H; CH3); 1.6, 8.2H (8H;
CH2CH2CH2).
Conjugation of this carrier with MTX by the procedure de-
scribed for 19 gave yellowish, water-soluble conjugate in a yield
of 47%. 1H NMR data indicated the extent of NH2 substitution to
be 86%. The polymer was, therefore, retreated with 0.3, 0.3, and
0.6 equivalents of MTX, HBTU, and triethylamine, respectively.
This gave 21 in a recovery yield of 42%.
1H NMR, /ppm: 8.5–6.6 combined, 5H (5H; aromatic and
heteroaromatic CH of MTX); 4.55, 10H (10H; NHCH2NH). The
data indicate 100% of NH2 groups to be substituted, correspond-
ing to an MTX content of 25.8% by mass.
Conjugate 22. The carrier was obtained in 12% yield by the
general procedure described for the carrier of 19; however,
2-(dimethylamino)ethylamine was used in place of 3-(dimethyl-
amino)propylamine. The water-soluble carrier was collected in
21% yield.
1H NMR, /ppm: 4.55, 10H (10H; NHCH2NH); 2.8–2.7, 27H
(20H; NHCOCH2); 2.7–2.25, 39H (40H; CH2N(CH2)(CH2),
CH2NH2, CH2N(CH3)2; 2.2, 24.5H (24H; CH3); 1.6, 2.2H (2H;
CH2CH2CH2).
The carrier was conjugated with MTX by the general proce-
dure described for 19. There was obtained yellow, water-soluble
conjugate 22 in a yield of 36%.
1H NMR, /ppm: 8.5–6.6 combined, 5H (5H; aromatic and
heteroaromatic CH of MTX); 4.51, 10H (10H; NHCH2NH). The
extent of MTX incorporation was thus 100%, corresponding to
an MTX content of 27.8% by mass.
Conjugate 23. The water-soluble carrier required for this con-
jugate was synthesized in 15% yield by the general procedure
described for the preparation of the carrier of 19 with these mod-
ifications: 3-(dimethylamino)propylamine was replaced by
2-(dimethylamino)ethylamine, and N-(tert-butoxycarbonyl)-
4,7-dioxa-1,10-diazadecane was used in lieu of the N-BOC-1,3-
diaminopropane.
1H NMR, /ppm: 4,5, 10H (10H; NHCH2NH); 3.7–3.6, 8.6H (8H;
CH2OCH2); 2.8–2.3, 62H (60H; NHCOCH2, CH2N(CH2(CH2)),
CH2NH2, CH2N(CH3)2).
The carrier was conjugated with MTX by the procedure
described for 19. The yellow water-soluble conjugate was col-
lected in 44% yield.
1H NMR, /ppm: 8.5–6.6 combined, 4.25H (5H; aromatic and
heteroaromatic CH of MTX); 4.5, 10H (10H; NHCH2NH). An
extent of MTX incorporation of 85% is calculated from these
data. A retreatment as described for conjugate 4 gave polymer
with 93% MTX incorporation, corresponding to an MTX content
of 25.2% by mass.
1H NMR, /ppm: 8.5–6.6, 4.65H (5H); 4.5, 10H (10H).
Conjugate 24. The carrier was obtained in 12.5% yield as a
water-soluble polymer by the general procedure described for
the carrier of 19, yet with an equal amount of 2-(2-aminoethoxy)
ethanol used in place of 3-(dimethylamino)propylamine.
1H NMR, /ppm: 4.52, 10H (10H; NHCH2NH); 3.75–3.55, 23H
(24H; CH2OCH2CH2OH); 1.6, 1.8H (2H; CH2CH2CH2).
The procedure described for 19 was used for MTX conjugation
with the carrier, giving yellow, water-soluble conjugate in 48%
yield. 1H NMR data indicated 90% MTX incorporation. The poly-
mer was re-treated with MTX and coupling agent as described
for conjugate 4 (recovery, 64%).
1H NMR, /ppm: 8.5–6.6 combined, 4.7H (5H; aromatic and
heteroaromatic CH of MTX); 4.51, 10H (10H; NHCH2NH). The
data indicate 94% NH2 substitution, corresponding to an MTX
content of 25.5% by mass.
Conjugate 25. To the solution of methylenebisacrylamide,
1.24 g (8 mmol) in 4 mL of isopropanol-H2O (4:1) (gentle heating
required), was added N-(tert-butoxycarbonyl)-1,3-diamino-
propane, 698 mg (4 mmol), dissolved in 1 mL of isopropanol. The
solution, saturated with N2, was stirred for 3 d at ambient tem-
perature. The solvent was removed by rotatory evaporation,
and the residual intermediary monomer was redissolved in
50 mL of the same solvent blend, thus providing the high
dilution ([MBA] ≤ 0.2 M) required to prevent disubstitution
on N in the second reaction step. O,O’-Bis(3-aminopropyl)poly
(ethylene glycol) 1500, 6 g (4 mmol), was dissolved in the cooled
(~5°C) solution, followed by triethylamine, 405 mg (4 mmol).
Upon resaturation with N2, the solution was stirred overnight in
an ice bath, 1 d at ambient temperature, and for another 36 h at
60°C. The solvent was removed once more on the rotavapor,
5 mL of trifluoroacetic acid was added to the residue, and stirring
was continued for 1 h at room temperature. The acid was dis-
tilled off on the rotavapor (40°C bath temperature) and the resid-
ual material was treated with Et2O-hexane (1:1) and repeatedly
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washed with boiling toluene for removal of all traces of
unreacted poly(ethylene glycol). The crude polymer was puri-
fied by dialysis and isolated as described for 19. The yield of the
water- and methanol-soluble carrier was 2.1 g (27.8%).
1H NMR, /ppm: 4.54, 4H (4H; NHCH2NH); 2.8, 8.2H (8H;
NHCOCH2); 2.7–2.3, 14.8H (16H; CH2N(CH2)(CH2), CH2NH2,
CH2NHCH2); 1.8–1.55, 4.8H (6H; CH2CH2CH2).
The carrier, 200 mg (0.106 mmol), together with MTX, 69 mg
(0.149 mmol), was dissolved in 5 mL of DMF. HBTU, 49 mg
0.13 mmol), dissolved in 0.5 mL of the same solvent, was added
dropwise, and so was triethylamine, 22 mg (0.216 mmol). The
N2-saturated solution was stirred for 2 h at room temperature,
followed by cooling in an ice bath. The conjugate was precipi-
tated with excess Et2O-Me2CO and separated from the
supernatant by centrifugation. It was redissolved in 5 mL of
H2O, and the solution, with pH adjusted to 10, was passed
through Sephadex G-25, dialysed in Spectra/Por 6, and
freeze-dried as described for 1. The yellowish, water-soluble
conjugate was isolated in a yield of 130 mg (55%).
1H NMR, /ppm: 8.5–6.6 combined, 4H (5H; aromatic and
heteroaromatic CH of MTX; 4.5, 4H (4H; NHCH2NH); These
data indicate an 80% MTX incorporation, according to an MTX
content of 15.7% by mass. Attempted retreatment with MTX
failed to raise this percentage.
3. Results and Discussion
3.1. Conjugate Compositions
The polyaspartamide-MTX conjugates assayed in this study,
most of them obtained in the preceding investigations or newly
synthesized by the procedures there described1,20,21, conform to
the structures 1 to 18 depicted in Fig. 1. In 1 to 16 the bio-
fissionable groups in the connecting spacer are represented by
the carboxamide link, and the compounds were synthesized
from amine-functionalized polyaspartamides by a carboxyl-
amine coupling process mediated by the HBTU (2-(1H-benzo-
triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate)
or EEDQ (1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline)
coupling agents (Scheme 1; spacer = aliphatic segment). In con-
jugates 17 and 18 the biofissionable groups are represented by
an ester functionality, and the synthesis, starting out from
hydroxyl-functionalized polyaspartamides, proceeds by a
carboxyl-hydroxyl coupling step mediated by the DCC
(dicyclohexyl carbodiimide) coupling agent and catalysed by
DMAP (4-(dimethylamino)pyridine) (Scheme 2; spacer =
aliphatic segment). A unifying feature of the conjugates listed
in Fig. 1 is their copolymeric construction comprising sub-
units with hydrosolubilizing side group terminals of the tert-
amine (1 to 9) or hydroxyl (10 to 18) types in addition to other
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Figure 1
subunits containing the amide- or ester-coupled MTX molecule,
with x > y.
In view of the considerable run-to-run differences observed in
many instances, most of the conjugates were prepared in dupli-
cate or triplicate by de novo carrier synthesis and drug coupling.
Individual repeat runs are identified in Table 1 as Expt. 1, 2, and
3, as applicable.
The second class of MTX conjugates, newly synthesized and
investigated in this project, is based on poly(amidoamine)
carrier structures formed by a Michael polyaddition process
from bisacrylamides and amines. This type of Michael addition
reaction, pioneered by Ferruti’s group22 and amply utilized in
our own laboratory23–25, proceeds in aqueous phase. As the prop-
agation step is militated against by hydrolysis under the
common reaction conditions (3-4 d at ambient temperature or
shorter periods at 50–60°C), overall yields of polymer in the
required molecular mass region of about 20000–40000 are gener-
ally low. In a preceding project25, the chosen bisacrylamide
monomer, methylenebisacrylamide (MBA), was copolymerized
with pairs of amine comonomers, one of these a tert-amine- or
hydroxyl-functionalized primary amine introduced there as a
solubilizing entity, and the other, a diamine mono-N-protected
by the BOC (tert-butoxycarbonyl) group. N-deprotection with
trifluoroacetic acid and rigorous fractionation and purification
treatment then provided the desired primary amine-func-
tionalized poly(amidoamine) carriers. Seven carrier struc-
tures selected from that preceding investigation were used in
the present project. The carriers were coupled to MTX by the
standard procedures1 (Scheme 3). The individual structures
19 to 24 so obtained are listed in Fig. 2. Lastly, the described
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Scheme 1
Scheme 2
technology was utilized for a related poly(amidoamine)-MTX
conjugate 25 (Scheme 4; structure idealized, MTX incorporation
80%)25.
3.2. Cell Culture Testing
The conjugates of both classes were evaluated in cell culture
tests for antiproliferative activity. Members of the first class (con-
jugates 1 to 18) were tested against a moderately drug-resistant
cell line derived from the Colo 320 DM human colorectal carci-
noma, hereinafter briefly designated Colo (1). Selected conju-
gates were also tested against a more refractory, i.e. less
drug-responsive Colo 320 DM cell line variant, hereafter named
Colo (2). The latter line was also, exclusively, employed in the
tests of the members of the second class (19 to 25). For
comparison, the samples of both classes were separately
screened for activity against the HeLa human cervical epitheloid
adenocarcinoma line generally found to be drug-sensitive and
frequently used as a standard. Activities were determined in
triplicate by the earlier described procedure16, and the findings,
expressed as IC50 values (drug concentration required to achieve
50% cell kill relative to drug-free control) were averaged for each
sample. In order to obtain a measure of drug activity of the con-
jugates relative to unconjugated drug, we have also included
free MTX in these test series, and the results derived from five
determinations against each cell line, averaged for each line,
have been used for this comparison.
It is convenient to present and discuss the test results sepa-
rately for the two classes of conjugates.
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Table 1 Cell culture test data for Polyaspartamide-MTX conjugates.
Conjugate HeLa Colo (1)a Colo (2)a
IC50 AF
b IC50 AF
b IC50 AF
b
µg MTX Mc µg MTX Mc µg MTX Mc
/mL /mL /mL
1 Expt. 1d 0.067 1.48 × 10–7 2.1 0.027 5.95 × 10–8 42.8
Expt. 2 0.02 4.40 × 10–8 7.0 0.027 5.95 × 10–8 42.8
2 Expt. 1 0.075 1.65 × 10–7 1.9
Expt. 2 0.013 2.86 × 10–8 10.8 0.043 9.47 × 10–8 26.9 0.196 4.32 × 10–7 14.8
3 Expt. 1 0.119 2.62 × 10–7 1.2 0.050 1.10 × 10–7 23.1
Expt. 2 0.031 6.83 × 10–8 4.5 0.011 2.42 × 10–8 105.0
4 Expt. 1 0.037 8.15 × 10–8 3.8 0.030 6.61 × 10–8 38.5
5 Expt. 1 0.012 2.64 × 10–8 11.7 0.0079 1.74 × 10–8 146.2
6 Expt. 1 0.018 3.96 × 10–8 7.8 0.0053 1.17 × 10–8 217.9
Expt. 2 0.015 3.30 × 10–8 9.3 0.0046 1.01 × 10–8 251.1
Expt. 3 0.003 6.61 × 10–9 46.7 0.149 3.28 × 10–7 19.5
7 Expt. 1 0.019 4.19 × 10–8 7.4 0.013 2.86 × 10–8 88.8
Expt. 2 0.012 2.64 × 10–8 11.7 0.004 8.81 × 10–9 288.8
8 Expt. 1 0.027 5.95 × 10–8 5.2 0.075 1.65 × 10–7 15.4
Expt. 2 0.048 1.06 × 10–7 2.9 0.264 5.81 × 10–7 11.0
9 Expt. 1 0.01 2.20 × 10–8 14.0 0.031 6.83 × 10–8 37.3
Expt. 2 0.025 5.51 × 10–8 5.6 0.49 1.08 × 10–6 5.9
10 Expt. 1d 0.024 5.29 × 10–8 5.83 0.017 3.74 × 10–8 67.9
11 Expt. 1 0.689 1.52 × 10–6 0.20 1.084 2.39 × 10–6 2.7
Expt. 2 0.449 9.89 × 10–7 0.31 0.116 2.56 × 10–7 10.0
Expt. 3 0.379 8.35 × 10–7 0.4 1.214 2.67 × 10–6 2.4
12 Expt. 1 4.918 1.08 × 10–5 0.03 12.96 2.85 × 10–5 0.2
13 Expt. 1 0.0039 0.59 × 10–9 35.9 0.0093 2.05 × 10–8 124.2
14 Expt. 1 0.594 1.31 × 10–6 0.23 1.967 4.33 × 10–6 1.5
Expt. 2 0.261 5.75 × 10–7 0.54 0.154 3.39 × 10–7 7.5
Expt. 3 0.536 1.18 × 10–6 0.3 1.712 3.77 × 10–6 1.7
15 Expt. 1 0.0093 2.04 × 10–8 15.1 0.0034 7.49 × 10–9 339.7
Expt. 2 0.027 5.95 × 10–8 5.2 0.507 1.12 × 10–6 5.8
16  Expt. 1 4.228 9.31 × 10–6 0.03 16.37 3.61 × 10–5 0.2
17  Expt. 1 0.325 7.16 × 10–7 0.4 0.107 2.36 × 10–7 10.8
Expt. 2 0.159 3.50 × 10–7 0.9 0.064 1.41 × 10–7 18.0
18 Expt. 1 0.066 1.45 × 10–7 2.1 0.028 6.17 × 10–8 41.3
Expt. 2 0.195 4.30 × 10–7 0.7 0.080 1.76 × 10–7 14.4
Expt. 3 0.473 1.04 × 10–6 0.3 1.449 3.19 × 10–6 0.8
MTX 0.140 3.08 × 10–7 1.155 2.54 × 10–6 2.902 6.39 × 10–6
a Variants of Colo 320 DM: moderately resistant (1) and strongly resistant (2) lines.
b Activity factor, here defined as: IC50(MTX): IC50(Conjugate), rounded off to first or second decimal.
c Moles MTX/L.
d Expt.: refers to separately synthesized conjugates.
3.2.1. Polyaspartamide-MTX Conjugates
For the polyaspartamide-based conjugates 1 to 18, including
repeat runs, the IC50 values, in terms of µg MTX mL
–1 and µM
MTX, have been listed in Table 1 for the tests against HeLa and
the two Colo 320 DM variants. The table also contains the aver-
aged results shown by free MTX for each cell line. Furthermore,
we have included activity factors, AF, here defined as the ratio of
conjugate activities over MTX activity and expressed in terms of
IC50 (MTX):IC50 (conjugate).
It is instructive to consider first the data in the HeLa column. A
superficial examination reveals that IC50 values for the first
one-half of the listed conjugates are lower than that for MTX. For
these first 17 samples (conjugates 1 to 9) an averaged activity
factor of 4.3 can be calculated from the averaged IC50 values
(0.0324 µg MTX mL–1). These conjugates as a group, hence, are
some four times more active than the free drug. We recall that
these 17 samples are characterized by tert-amine side chain
terminals as hydrosolubilizing groups in R1.
The situation is different for the second one-half of the tabu-
lated samples (conjugates 10 to 18) identified by hydroxyl side
chain terminals in R1. For these 17 samples the averaged IC50
value, 0.889 µg MTX mL–1, suggests an average activity factor of
0.16, thus reflecting a reverse behaviour, with free MTX now
some six times more active than the samples as a group. It is clear
that, against the HeLa line, the tert-amine functionality in conju-
gates 1 to 9 exerts a positive influence on the in vitro cyto-
toxic data. In the biological environment, this functionality is
partially protonated, which renders the polymer moderately
basic and may thus facilitate pinocytic cell entry with resul-
tant activity enhancement26. Larger sample numbers will be
required, however, to corroborate this explanation.
An even more favorable constellation emerges as one inspects
the IC50 values in the two Colo columns. Let us first consider the
Colo (1) data. Against this moderately refractory cell line, free
MTX, as expected, encounters some eight times higher resis-
tance (IC50[Colo (1)]:IC50[HeLa] = 8.25). In stark contrast, the
conjugates as a group experience practically no resistance rela-
tive to HeLa. In fact, 18 of the total of 23 samples tested show IC50
values lower than observed in the tests against HeLa, indicating
higher activity against the ostensibly resistant line than against
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Scheme 3
Figure 2
the sensitive one. Compared with IC50 of free MTX in this column
(1.155 µg MTX mL–1), all samples except one (conjugate 18,
Expt. 3) are distinctly more active than the free drug. From the
averaged IC50, 0.1025 µg MTX/mL, an activity factor of 11.3 is
calculated, indicating the 23 samples as a group to exceed the
free drug more than 10-fold in activity.
More specifically, considering the first 13 samples of conju-
gates 1 to 9, we determine average values of IC50 and activity fac-
tors of 0.0253 µg MTX mL–1 and 45.7, respectively, for these conju-
gates in toto. Individually within this group of tert-amine-
functionalized conjugates, five samples are over 100-fold more
active than MTX. Even the 10 hydroxyl-functionalized samples
of conjugates 10 to 18 in toto give an average activity factor of 5.69
derived from the averaged IC50 data (0.2028 µg MTX mL
–1).
Let us proceed now to the Colo (2) column. To the unconju-
gated drug, the Colo (2) line proves to be some 20 times more
refractory than HeLa, which clearly identifies that Colo variant
as a strongly drug-resistant line. Here, for the first four samples
listed in this column (conjugates 2, 6, 8, and 9) the averaged IC50
value (0.275 µg MTX mL–1) leads to an average activity factor of
10.55, showing these tert-amine-functionalized polymers as
a group to be over 10 times more active than free MTX. The
following seven samples in the category of hydroxyl-func-
tionalized conjugates (11, 12, 14, and 16) are distinctly less active
as a group against this strongly resistant line. With an activity
ratio of 0.57, derived from the averaged IC50 values (5.1162 µg
MTX mL–1), they are even less active than the free drug. This
average AF value is misleading, however, being strongly
affected by the two outsiders (possibly artifacts), the conjugates
12 and 16. If these are omitted from the calculations, an activity
factor of 2.24 results from the averaged IC50 value (1.2968 µg
MTX mL–1). This indicates that even these hydroxyl-func-
tionalized conjugates for the most part are twice as active as the
unconjugated drug.
3.2.2. Poly(amidoamine)-MTX Conjugates
This class comprises a small number of conjugates (19 to 25;
one sample per conjugate) made available for a very preliminary
evaluation of activities against the HeLa and Colo (2) lines. The
results in terms of IC50 and activity factor are presented in Table 2,
which includes data obtained in this test series for unconjugated
MTX.
We shall first inspect the data in the HeLa column. For the first
five conjugates 19 to 23, characterized by the presence of
tert-amine terminals on short side chains functioning as hydro-
solubilizing moieties, the IC50 values approximate that of
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Scheme 4
Table 2 Cell culture test data for poly(amidoamine)-MTX conjugates.
HeLa Colo (2)a
Conjugate IC50 AF
b IC50 AF
b
µg MTX Mc µg MTX Mc
/mL /mL
19 0.134 2.95 × 10–7 0.6 1.348 2.97 × 10–6 3.1
20 0.014 3.08 × 10–8 5.7 0.089 1.96 × 10–7 12.9
21 0.058 1.28 × 10–7 1.4 0.884 1.86 × 10–6 4.9
22 0.086 1.89 × 10–7 0.9 0.675 1.49 × 10–6 6.1
23 0.025 5.51 × 10–8 3.2 1.719 3.79 × 10–6 2.4
24 2.659 5.86 × 10–6 0.03 15.62 3.44 × 10–5 0.27
25 1.324 2.92 × 10–6 0.06 9.58 2.11 × 10–5 0.43
MTX 0.08 1.76 × 10–7 4.15 9.14 × 10–6
a Strongly resistant variant of Colo 320 DM. See text.
b Activity factor. For definition, see footnote b, Table 1.
free MTX. The average activity factor, 1.26, derived from the
averaged IC50 data (0.0634 µg MTX mL
–1), identifies this group of
conjugates as slightly more active than MTX proper. Conju-
gate 24, in contrast, containing a hydroxyl side chain terminal for
solubilization, gives an activity factor of 0.03, and 25, with a
solubilizing intrachain oligo(ethylene oxide) segment, provides
an AF of 0.06. The activities of these two conjugates are thus
considerably lower than that of MTX.
The same basic trend is apparent for all conjugates from the
Colo data. While conjugates 19 to 23 as a group are five times
more active than free MTX, with averaged IC50 = 0.783 µg
MTX mL–1 and resultant AF = 5.3, the remaining two conjugates
turn out to be less active than free MTX, with activity factors
of 0.27 and 0.43, respectively. In compound 24, the presence of
the hydroxyl (rather than tert-amine) side group most likely
accounts for the inferior performance against both cell lines in
accordance with the trend described above for the poly-
aspartamide-MTX conjugate series. The oligo(ethylene oxide)
segment in 25 possesses protein-repellant characteristics, and
this may lead to inhibition of intracellular enzymatic cleavage of
the drug-binding carboxamide links and resultant lower
bioavailability.
In conclusion, cell culture tests performed against the
drug-sensitive HeLa and the two moderately or strongly resis-
tant Colo lines reveal a vastly superior cell killing potential for
polymer-bound MTX as a class in relation to the unconjugated
drug. Best performers belong to the group of polyaspartamide-
based conjugates featuring tert-amine side chain terminals as
hydrosolubilizing entities, with selected compounds some 10 to
100 times more active than free MTX. The superiority of this
group of conjugates is particularly apparent in tests against the
resistant Colo (1): whereas free MTX displays an activity
decreased over 10-fold relative to HeLa, the conjugates as a
group are even more active against this resistant line than
against the sensitive HeLa standard. While in tests against
Colo (2) all compounds show lowered cytotoxic performance,
this loss of activity is much less severe with the polymeric
than with the monomeric drug. Polyaspartamide-bound MTX
derivatives, notably those containing tert-amine side chain
terminals, thus stand out as eminently promising candidates for
further bioevaluation work in tests against both sensitive and
multidrug-resistant cancer cells.
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